metaEvidence - study list

meta|evidence oncology

Living systematic review and meta-analysis

metastatic/advanced - esophageal cancer (mEC)
mEC - (neo)adjuvant (NA) 1
mEC - 1st line (L1) 1
mEC - 2nd line (L2) 3
gastric or gastroesophageal junction cancer (GC)

All treatments
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab alone
Ipilimumab (10 mg/kg)
anti-PD-(L)1
avelumab based treatment
avelumab alone
nivolumab based treatment
nivolumab alone
nivolumab plus SoC
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus SoC

versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs taxanes
vs paclitaxel
vs Standard of Care (SoC)
vs placebo plus SoC
vs non active control
vs placebo

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results

delta: difference in rate or median (if available)

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open